Daniel R. Cherñavvsky, MD Dr. Cherñavvsky received his medical degree from the University of Buenos Aires, Argentina. He completed his pediatric residency at the Children’s Hospital in Buenos Aires and his fellowship in pediatric nephrology at the Italian Hospital in Buenos Aires. He came to the University of Virginia in 1997 as a research fellow where his primary research was in kidney development. A highlight of his achievement during those years is his publication with Nobel laurate, Dr. Oliver Smithies on Bartter Syndrome. He joined the faculty at UVA, and his seminal work was in the Center for Diabetes Technology where he was part of the development of the first closed-loop system tested in humans. He coordinated the 1st USA outpatient clinical trial of an artificial pancreas in 2011. He also conducted the 1st clinical trial using Artificial Pancreas in Latin America in 2016. As part of the UVA Center for Diabetes Technology, he conducted more than 30 clinical trials in five countries (four continents) enabling emerging technology to be tested and later used for treatment of diabetes in children, adolescents, and adults. Dr. Chernavvsky is the author or co-author of numerous peer review articles, and he is senior editor for the first edition of the Artificial Pancreas published in April 2019. In 2017, he joined TypeZero as a Chief Medical Officer and in 2019 he joined Dexcom as Senior Director of Medical Affairs. He is part of the group that enabled the use of CGM for inpatients during the pandemic and is currently the clinical lead that seeks to have Dexcom CGM approved for use in hospital settings.